4565Nxera Pharma Co.,Ltd.¥ --

Nxera Pharma Co.,Ltd.

4565

TSE PrimePharmaceuticals

¥ -

Nxera Pharma Co.,Ltd. (4565) statement of comprehensive income, including other comprehensive income and total comprehensive income.

The statement of comprehensive income shows net income alongside other comprehensive income, including currency translation and changes in asset values.

Statement of Comprehensive Income Details

IFRS　Unit: JPY

Item

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

Revenue

Cost of sales

Gross profit

Research and development expenses

Selling, general and administrative expenses

Other income

Other expenses

Operating loss

Finance income

Finance costs

Loss before tax

Income tax expense

Profit/Loss

Valuation Difference on Available-for-sale Securities (OCI)

Total of Items That Will Not Be Reclassified to Profit or Loss

Foreign Currency Translation Adjustment (OCI)

Total of Items That May Be Reclassified to Profit or Loss

Total Other Comprehensive Income

Comprehensive Income

Owners of Company

Comprehensive Income Attributable to Owners of Parent

Basic loss per share

Diluted loss per share

29.6B

8.2B

21.4B

14.5B

15.2B

1.7B

1.8B

-8.5B

987.0M

7.5B

-14.9B

-2.4B

-12.5B

188.0M

2.9B

3.1B

-9.5B

-12.5B

-9.5B

-139

Unlock Long-Term Financial Data

Your current plan allows viewing financial data for the latest 1 year (annual only). Upgrade to the Standard Plan to view up to 3 years (including quarterly data), or the Premium Plan to access all historical data.

Standard Plan Premium Plan